Apollomics Inc. (APLM)
6.56
0.34 (5.55%)
At close: Apr 25, 2025, 3:20 PM
6.74
2.74%
After-hours: Apr 25, 2025, 05:05 PM EDT
5.55% (1D)
| Bid | 6.31 |
| Market Cap | 7.24M |
| Revenue (ttm) | 2.27M |
| Net Income (ttm) | -57.11M |
| EPS (ttm) | -52.8 |
| PE Ratio (ttm) | -0.12 |
| Forward PE | -0.05 |
| Analyst | Buy |
| Ask | 7.09 |
| Volume | 11,451 |
| Avg. Volume (20D) | 24,004 |
| Open | 5.66 |
| Previous Close | 6.21 |
| Day's Range | 5.66 - 6.86 |
| 52-Week Range | 4.71 - 49.00 |
| Beta | 0.94 |
About APLM
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 26, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol APLM
Website https://www.apollomicsinc.com
Analyst Forecast
According to 1 analyst ratings, the average rating for APLM stock is "Buy." The 12-month stock price forecast is $200, which is an increase of 2948.78% from the latest price.
Stock Forecasts3 weeks ago
-10.58%
Apollomics shares are trading lower. The company r...
Unlock content with
Pro Subscription
4 weeks ago
-18.53%
Apollomics shares are trading higher after the company announced a development and commercialization agreement for Vebreltinib.
